%0 Journal Article %T Cannabinoid receptors as novel therapeutic targets for the management of non-alcoholic steatohepatitis. %+ Institut Mondor de recherche biomédicale (IMRB) %+ Service d'hépato-gastro-entérologie [APHP Henri Mondor] %A Mallat, Ariane %A Lotersztajn, Sophie %< avec comité de lecture %@ 1262-3636 %J Diabetes & Metabolism %I Elsevier Masson %V 34 %N 6 Pt 2 %P 680-4 %8 2008-12 %D 2008 %R 10.1016/S1262-3636(08)74604-4 %M 19195630 %K fatty liver %K non alcoholic steatohepatitis %K endocannabinoids %K cannabinoid receptors %K liver fibrosis %Z Life Sciences [q-bio]/Biochemistry, Molecular BiologyJournal articles %X Prevalence of non-alcoholic steatohepatitis (NASH) rises steadily in Western countries with the obesity epidemic. NASH is associated with activation of liver fibrogenesis and predisposes to cirrhosis and associated morbi-mortality. The cannabinoid system is increasingly emerging as a crucial mediator of acute and chronic liver injury. Recent experimental and clinical data indicate that peripheral activation of cannabinoid CB1 receptors promotes insulin resistance and liver steatogenesis, two key steps in the pathogenesis of non-alcoholic fatty liver disease. Moreover, CB1 receptors enhance progression of liver fibrogenesis. These findings provide a strong rationale for the use of CB1 antagonists in the management of NASH. %G English %2 https://inserm.hal.science/inserm-00371854/document %2 https://inserm.hal.science/inserm-00371854/file/inserm-00371854_edited.pdf %2 https://inserm.hal.science/inserm-00371854/file/Diabetes_and_metbolism_Cannabinoids_AND_NASH_2008_A_Mallat.pdf %L inserm-00371854 %U https://inserm.hal.science/inserm-00371854 %~ INSERM %~ APHP %~ IMRB %~ UPEC